P&G Stock Solid In Third Quarter As Prilosec OTC Off And Running
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble's ability to differentiate Prilosec OTC as a proton-pump inhibitor versus available H2 antagonist heartburn products could give the firm a competitive advantage in the category and garner positive Wall Street attention